[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537223":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":27,"locations":34,"responsibleParty":54,"collaborators":18,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":18,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Tata Memorial Centre","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","Participants in the experimental arm (memantine) will be started on memantine. The starting dose of memantine will be 5mg once daily at bedtime for 1 week, followed by 5mg twice daily for 1 week, and finally increased to the full dose of 10 mg twice daily for 6 months.",[13],"Drug: Memantine Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard arm","NO_INTERVENTION","Participants in the standard arm will continue the standard treatment as planned.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Memantine Oral Tablet","Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy",[9],[26],"Memantine",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Tejpal Gupta, MD","CONTACT","02224177000","6015","drtejpalgupta@gmail.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Tata Memorial Hospital","RECRUITING","Mumbai","Maharashtra","400012","India","IN",{"type":44,"coordinates":45},"Point",[46,47],72.88261,19.07283,{"lat":47,"lon":46},[50],{"name":51,"role":30,"phone":52,"phoneExt":32,"email":53},"Dr Tejpal Gupta, MD","022-24177000","tejpalgupta@rediffmail.com",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Dr. Tejpal Gupta","Dr Tejpal Gupta, Professor, Department of Radiation Oncology","100537223","phase-3-evaluation-of-memantine-in-the-preservation-of-memory-and-neurocognition-following-csi-100537223",false,"NCT06275035","Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI","Memantine to Preserve Memory and Neurocognition Following Craniospinal Irradiation- A Randomised Controlled Trial (MEMENTO)","MEMENTO","Inclusion Criteria:\n\n* Age at irradiation: 5 to 39 years\n* Planned for CSI (with or without boost dose) with or without systemic chemotherapy\n* Informed consent or assent taken\n* Karnofsky Performance Status \u002F Lansky Performance Status ≥ 60\n\nExclusion Criteria:\n\n* Re-irradiation\n* Prior exposure to memantine\n* Inability to undergo Wechsler test","ALL","5 Years","39 Years",{"count":70,"type":71},101,"ESTIMATED","INTERVENTIONAL",[74],"PHASE3","The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.",[77],"Neurocognitive Dysfunction","2025-04-08",{"date":80,"type":81},"2025-04-09","ACTUAL",{"date":83,"type":81},"2024-02-22",{"date":85,"type":71},"2031-01",{"name":5,"class":6},1]